Merck (MRK) Current Deferred Tax Assets (2009 - 2023)
Merck (MRK) posted quarterly Current Deferred Tax Assets of $6.6 billion for Q2 2023, down 2.51% year-over-year from $6.8 billion in Q2 2022, and down 1.45% quarter-over-quarter from $6.7 billion in Q1 2023.
Merck (MRK) Current Deferred Tax Assets (2009 - 2023) Analysis & Trends
Merck (MRK) has reported Current Deferred Tax Assets for 15 consecutive years, with $6.6 billion the latest figure, recorded in Q2 2023.
- In Q2 2023, Current Deferred Tax Assets fell 2.51% year-over-year to $6.6 billion; the TTM figure through Jun 2023 stood at $6.6 billion (down 2.51% YoY), while the FY2022 annual figure was $7.2 billion, up 2.6% from the prior year.
- Current Deferred Tax Assets slipped to $6.6 billion in Q2 2023 per MRK's latest filing, from $6.7 billion in the prior quarter.
- Across five years, Current Deferred Tax Assets topped out at $7.2 billion in Q3 2022 and bottomed at $3.2 billion in Q1 2019.
- Historically, Current Deferred Tax Assets has averaged $5.6 billion across 5 years, with a median of $6.0 billion in 2021.
- Annual changes were most pronounced in 2019 — Current Deferred Tax Assets slipped 21.38% — and 2021, when it soared 49.49%.
- Merck's Current Deferred Tax Assets stood at $4.3 billion in 2019, then climbed by 9.28% to $4.7 billion in 2020, then jumped by 49.49% to $7.0 billion in 2021, then rose by 2.6% to $7.2 billion in 2022, then retreated by 7.39% to $6.6 billion in 2023.
- Business Quant data shows MRK's Current Deferred Tax Assets at $6.6 billion in Q2 2023, $6.7 billion in Q1 2023, and $7.2 billion in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 6.64 Bn |
| Jun 30, 2023 | 6.64 Bn |
| Mar 31, 2023 | 6.74 Bn |
| Mar 31, 2023 | 6.74 Bn |
| Dec 31, 2022 | 7.17 Bn |
| Dec 31, 2022 | 7.17 Bn |
| Sep 30, 2022 | 7.22 Bn |
| Sep 30, 2022 | 7.22 Bn |
| Jun 30, 2022 | 6.81 Bn |
| Jun 30, 2022 | 6.81 Bn |
| Mar 31, 2022 | 6.65 Bn |
| Mar 31, 2022 | 6.65 Bn |
| Dec 31, 2021 | 6.99 Bn |
| Dec 31, 2021 | 6.99 Bn |
| Sep 30, 2021 | 6.87 Bn |
| Sep 30, 2021 | 6.87 Bn |
| Jun 30, 2021 | 6.75 Bn |
| Jun 30, 2021 | 6.75 Bn |
| Mar 31, 2021 | 5.29 Bn |
| Mar 31, 2021 | 5.29 Bn |